TQB2102 for advanced gynecologic cancers with HER2
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new targeted drug, TQB2102, for women with advanced or recurrent gynecologic cancers that have some HER2 protein. It may be an option if your cancer has continued to grow after platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with advanced gynecologic cancer that has come back or spread.
- Your tumor must have some HER2 protein (tested as 1+, 2+, or 3+).
- You have tried platinum-based chemotherapy before and it didn't work well.
- You have at least one tumor that can be seen and measured on a scan.
- You are not currently pregnant and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new drug, TQB2102, for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene and has stopped responding to standard treatments. It aims to see if the drug can shrink or slow the cancer.
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
Hear when a new Gynecological Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.